Comparative Pharmacology
Head-to-head clinical analysis: 8 MOP versus OXSORALEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: 8 MOP versus OXSORALEN.
8-MOP vs OXSORALEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
8-MOP (methoxsalen) is a psoralen compound that intercalates into DNA. Upon UVA irradiation, it forms covalent cross-links between pyrimidine bases, inhibiting DNA synthesis and cell division. It also reduces the proliferation of epidermal cells and suppresses cutaneous immune responses by inhibiting antigen presentation and cytokine release.
Psoralen intercalates into DNA and upon UVA exposure forms covalent crosslinks between pyrimidine bases, inhibiting DNA synthesis and cell proliferation.
Psoriasis: 0.4–0.6 mg/kg orally 2 hours before UVA exposure, 2–3 times per week. Vitiligo: 20 mg (0.3–0.4 mg/kg) 2 hours before UVA. Dose adjusted based on skin type and UVA dose.
0.6 mg/kg orally once daily, 2 hours before UV-A exposure, or 0.4 mg/kg orally 2 hours before psoralen plus UV-A (PUVA) therapy. For topical use, a 1% lotion is applied 2 hours prior to UV-A exposure.
None Documented
None Documented
Terminal elimination half-life is 1–2 hours; however, clinical effect persists longer due to sustained phototoxic reaction.
Approximately 2-5 hours for parent drug; clinical effect persists longer due to epidermal DNA binding.
Renal excretion of metabolites (~95%) with <0.5% unchanged; biliary/fecal elimination ~5%.
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for the majority of metabolites, though exact percentage not well defined.
Category C
Category C
Psoralen
Psoralen